911PPatients (pts) with metastatic non clear cell renal cell carcinoma (mnccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of …

Background: Immunotherapy with the andi-PD1 Nivo is a standard ATL for clear cell mRCC. Data on its activity in the rare variant of mnccRCC is limited (case reports). We aimed to report the activity of Nivo in mnccRCC pts treated per a national EAP.Methods: Records from consecutive mnccRCC pts treated with Nivo ATL per a national EAP in 6 centers were retrospectively reviewed. We report the clinical benefit, progression free survival (PFS), overall survival (OS), and toxicity.Results: Between 7/2015–12/2016, 16 mnccRCC pts (median age 64, male 68%; papillary type 38%, n= 6; chromophobe 44%, n= 7; undifferentiated 12%, n= 2; pure sarcomatoid 6%, n= 1). 62%(n= 10) were treated with second line Nivo, and 38%(n= 6) as third...